-
-
封面介绍CDK4/6 inhibitors have become pivotal therapeutic agents in the treatment of breast cancer, lung cancer, and other malignancies. A systematic examination of the synthetic routes of eight representative compounds— palbociclib and dalpiciclib, ribociclib and volbociclib, abemaciclib and tericiclib, as well as trilaciclib and lerociclib—selected based on their time of market authorization and structural homology, is provided by Li, Gao, and Zhang on page 315. Special emphasis is placed on the role of novel reaction systems and advanced synthetic strategies in enhancing process efficiency.
-
-
本期栏目
综述与进展
研究论文
研究简报
亮点述评